AstraZeneca
Aggregated from S&P 500 earnings calls
Total Mentions
3
Companies
1
Sentiment
NEUTRAL 1
Mentions by Company
Merck & Co. Inc.Q3-2025
3×NEUTRAL
“Amendment to the collaboration agreement with AstraZeneca, which discontinued the provisions whereby the Company shared revenue and costs”
“Benefit of approximately $0.09 per share resulting from an amendment to the collaboration agreement with AstraZeneca related to Koselugo”